Fractional Resurfacing Device for Treatment of Acne Scarring

• ClinicalTrials.gov Identifier: NCT00585286
• Recruitment Status: Completed
• First Posted: January 3, 2008
• Results First Posted: December 2, 2013
• Last Update Posted: January 15, 2014
• Sponsor: University of California, Irvine
• Collaborators: Reliant Technologies, Inc. Mountain View, CA; University of Minnesota
• Information provided by (Responsible Party): Christopher Zachary, University of California, Irvine

Study Description

Brief Summary:

The purpose of this research study is to evaluate the safety and effectiveness of a new investigational laser device for treatment of acne scarring, for improvement in the appearance of surface texture and topography (recessed or uneven surfaces).

Condition or disease	Intervention/treatment	Phase
Acne; Scar	Device: 10,600 nm fractional carbon dioxide laser system	Phase 1; Phase 2

Detailed Description:

Thirty subjects between two research locations with an acne scar severity score greater than 4 will receive up to 3 treatments with an FDA IDE and Institutional Review Board approved 10,600nm fractional carbon dioxide laser system. Improvement of acne scarring is evaluated at 1 month and 3 months post-treatment.

Post-treatment responses evaluated are immediate erythema, immediate edema, and any other immediate responses. Evaluations are conducted immediate post treatment and one week post-treatment. Key safety data include the severity scoring of post-treatment responses, as well as by photodocumentation.

The incidence of side effects such as scarring, pigmentary changes, etc. are evaluated at follow-up visits one and three months post-treatment. Key safety data include the incidence rates and severity scoring of side effects, as well as by photodocumentation

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 15 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Evaluation of a Novel Fractional Resurfacing Device for the Treatment of Acne Scarring
• Study Start Date: March 2007
• Actual Primary Completion Date: July 2008
• Actual Study Completion Date: July 2008

Arms and Interventions

Arm	Intervention/treatment
Experimental: Fractional carbon dioxide laser system; Thirty total healthy subjects from two research centers with skin type I-IV of moderate to severe acne scarring received treatment with the 10,600 nm fractional carbon dioxide laser system.	Device: 10,600 nm fractional carbon dioxide laser system; 1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2; Other Name: Fraxel Re:pair laser

Outcome Measures

Primary Outcome Measures :

1. Overall Improvement of Acne Scarring [ Time Frame: Baseline, 1 month and 3 months post-treatment ]
   Subject assessment of the percent improvement of acne scarring compared to baseline and based on the quartile scale (0: no improvement; 1: 1-25% improvement; 2: 26-50%; 3: 51-75%; 4: 76-100% improvement).
2. Average Improvement in Surface Texture [ Time Frame: Baseline, 1 month and 3 months post-treatment ]
   Subject assessment of the percent improvement of surface texture compared to baseline and based on the quartile scale (0: no improvement; 1: 1-25% improvement; 2: 26-50%; 3: 51-75%; 4: 76-100% improvement).
3. Degree of Atrophy [ Time Frame: Baseline, 1 month and 3 months post-treatment ]
   Subject assessment of the percent improvement in extent of atrophy compared to baseline and based on the quartile scale (0: no improvement; 1: 1-25% improvement; 2: 26-50%; 3: 51-75%; 4: 76-100% improvement).

Secondary Outcome Measures :

1. Pain Tolerance [ Time Frame: At treatment visit (up to 3 visits) ]
   The average pain score reported over all three treatments was 5.67, corresponding to "moderate" pain based on a 10-point scale. The pain score is recorded on a 10-point scale, with 0 being "no pain" and 10 being "worst pain imaginable." All subjects reported that any discomfort associated with the procedure was only during active intervention and resolved immediately post-procedure. Increased pain scores correlated with increased density, but not increased energy.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Have Fitzpatrick skin type I-V. (Type I is blonde/red hair with freckles and Type V are Hispanics and lighter African Americans.)
• Are male or female.
• Are between 18 and 75 years of age.
• Have moderate to severe acne scarring. Acne scarring will be assessed with the Acne Scar Severity Scale. Subjects will be eligible for treatment if the area to be treated is scored as having an Acne Scar Severity Score > 4 according to the Acne Scar Severity Scale (0-9).
• Are able to read, understand, and sign the Informed Consent.
• Are willing and able to comply with all follow-up requirements for a minimum of 8 months.

Exclusion Criteria:

• Have had active localized or systemic infections within 6 months of enrollment
• Have compromised ability for wound healing, such as: malnutrition, oral steroid use, history of collagen vascular disease (e.g. lupus, scleroderma, history of keloid formation (raised and thickened scars), atrophic dermatitis (extreme skin irritation or itchiness) or immunologic abnormalities such as vitiligo (white patches of skin due to loss of pigment)
• Have immunocompromised status (inability to resist infection, etc.)
• Have been treated with lasers, chemical procedures, or other cosmetic procedures on the area to be treated within 6 months of enrollment
• Have taken Accutane within 12 months of enrollment
• Are allergic to lidocaine (skin numbing agent)
• Are allergic to Valtrex (an anti-viral medication)

Contacts and Locations

Locations

United States, California

UC Irvine Dermatology Clinical Research Center

Irvine, California, United States, 92697

Sponsors and Collaborators

University of California, Irvine

Reliant Technologies, Inc. Mountain View, CA

University of Minnesota

Investigators

• Principal Investigator: Christopher B Zachary, MBBS, FRCP; University of California, Irvine
• Principal Investigator: Brian D Zelickson, MD; Department of Dermatology, University of Minnesota, Minneapolis, Minnesota

More Information

Additional Information:

University of California, Irvine Department of Dermatology Clinical Research 

• Responsible Party: Christopher Zachary, Clinical Professor, University of California, Irvine
• ClinicalTrials.gov Identifier: NCT00585286
• Other Study ID Numbers: 2006-5328
• First Posted: January 3, 2008
• Results First Posted: December 2, 2013
• Last Update Posted: January 15, 2014
• Last Verified: December 2013

Keywords provided by Christopher Zachary, University of California, Irvine:

acne vulgaris; scarring; laser

Additional relevant MeSH terms:

Cicatrix; Fibrosis; Pathologic Processes